January 8, 2018 / 2:05 PM / 4 months ago

BRIEF-Five Prime Therapeutics Earns IND Milestone Payment Under Immune Checkpoint Pathways Discovery Collaboration With Bristol-Myers Squibb

Jan 8 (Reuters) - Five Prime Therapeutics Inc:

* FIVE PRIME THERAPEUTICS EARNS IND MILESTONE PAYMENT UNDER IMMUNE CHECKPOINT PATHWAYS DISCOVERY COLLABORATION WITH BRISTOL-MYERS SQUIBB AND ANNOUNCES THAT BMS HAS EXTENDED THE RESEARCH TERM OF THIS COLLABORATION FOR A SECOND TIME

* FIVE PRIME THERAPEUTICS INC - MILESTONE FOR ANTIBODY TARGETING TIM-3 TRIGGERS $5 MILLION PAYMENT TO FIVE PRIME

* FIVE PRIME- BMS EXTENDS RESEARCH COLLABORATION TERM FOR DEVELOPMENT, COMMERCIALIZATION FOR THERAPEUTICS IN 3 IMMUNE CHECKPOINT PATHWAYS TO MARCH 2019

* FIVE PRIME THERAPEUTICS INC - BRISTOL-MYERS SQUIBB WILL ALSO PROVIDE ADDITIONAL FUNDING TO FIVE PRIME FOR EXTENDED TERM OF RESEARCH COLLABORATION Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below